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http://www.biomedcentral.com/1471-2407/14/360RESEARCH ARTICLE Open AccessTIMP-1 and responsiveness to gemcitabine
in advanced breast cancer; results from a
randomized phase III trial from the Danish
breast cancer cooperative group
Charlotte Levin Tykjær Jørgensen1*, Christina Bjerre2, Bent Ejlertsen3,4, Karsten D Bjerre3, Eva Balslev1,
Annette Bartels2, Nils Brünner2 and Dorte L Nielsen5Abstract
Background: Tissue inhibitor of metalloproteinases-1 (TIMP-1) has anti-apoptotic functions, which may protect
TIMP-1 positive cancer cells from the effects of chemotherapy such as docetaxel and gemcitabine. The purpose of
the present study was to evaluate TIMP-1 immunoreactivity as a prognostic and predictive marker in advanced
breast cancer patients receiving docetaxel (D) or gemcitabine plus docetaxel (GD).
Methods: Patients with locally advanced or metastatic breast cancer who were assigned to D or GD by
participation in a randomized phase III trial were included in the study. Assessment of TIMP-1 status was performed
retrospectively on primary tumor whole-tissue sections by immunohistochemistry and tumor samples were
considered positive if epithelial breast cancer cells were stained by the anti-TIMP-1 monoclonal antibody VT7.
Time to progression (TTP) was the primary endpoint. Overall survival (OS) and response rate (RR) were secondary
endpoints. Associations between TIMP-1 status and outcome after chemotherapy were analyzed by Kaplan-Meier
estimates and Cox proportional hazards regression models.
Results: TIMP-1 status was available from 264 of 337 patients and 210 (80%) of the tumors were classified as
cancer cell TIMP-1 positive. No significant difference for TTP between TIMP-1 positive versus TIMP-1 negative
patients was observed in multivariate analysis, and RR did not differ according to TIMP-1 status. However, patients
with TIMP-1 positive tumors had a significant reduction in OS events (hazard ratio = 0.71, 95% confidence interval
(CI) = 0.52-0.98, P = 0.03). Additionally, a borderline significant interaction for OS was observed between TIMP-1
status and benefit from GD compared to D (Pinteraction = 0.06) such that median OS increased by nine months for
TIMP-1 negative patients receiving GD.
Conclusions: TIMP-1 status was an independent prognostic factor for OS but not TTP in patients with advanced
breast cancer receiving either D or GD. There was no statistically significant interaction between TIMP-1 status and
treatment, but a trend towards an incremental OS from the addition of gemcitabine to docetaxel in patients with
TIMP-1 negative tumors suggests further investigation.
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In advanced breast cancer, chemotherapy is used for pa-
tients with estrogen receptor (ER) negative, endocrine re-
sistant, or rapidly progressive disease to offer symptom
control and improve survival. Whether to use combination
chemotherapy or a sequential single agent chemotherapy
strategy remains unclear. Combination chemotherapy is as-
sociated with higher response rates (RR) and improved time
to progression (TTP) but the survival benefit is at its best
modest and often linked with increased toxicity [1]. There-
fore there is a need for tools that can identify those patients
who will benefit the most from combination chemotherapy.
Breast cancer is recognized as a heterogeneous disease
and response to treatment seems to depend on molecu-
lar characteristics of the tumor, some of which confer
resistance to specific drugs while others confer a more
multiresistant phenotype covering several different drug
classes [2-8]. Predictive markers may serve as tools for
tailoring therapy for individual patients, yet the number
of clinically useful markers is still limited [9-11].
Tissue inhibitor of metalloproteinases-1 (TIMP-1) is a
multifunctional protein, where some of its functions are re-
lated to the inhibition of matrix metalloproteinases (MMPs)
while other biological functions are MMP-independent,
such as inhibition of apoptosis and stimulation of prolif-
eration [12-16]. A prognostic value of TIMP- 1 in pri-
mary breast cancer has been suggested in several studies,
with high plasma or tumor tissue content of TIMP-1
being associated with poor patient outcome [15-19].
Moreover, breast cancer patients with TIMP-1 positive
cancer cells [2,8,20,21] seem to benefit less from adju-
vant anthracycline-containing chemotherapy. Docetaxel
(D), a taxane disrupting the dynamic function of micro-
tubules [22], and gemcitabine (G), a pyrimidine analog
arresting DNA replication and synthesis [23-25], are
widely used in breast cancer therapy [26,27]. A phase III
clinical trial by the Danish Breast Cancer Cooperative
Group (DBCG) [28] compared the efficacy of D versus
GD in patients with locally advanced or metastatic
breast cancer. GD increased TTP by two months com-
pared to D alone, while RR and overall survival (OS)
were similar [28]. The purpose of the present study was
to assess the potential predictive and prognostic infor-
mation provided by TIMP-1 in patients participating in
this trial. We have previously shown a differential benefit
in these patients from the addition of G to D depending
on intrinsic molecular subtype [29], and consequently we
additionally sought to clarify whether a possible effect of
TIMP-1 was independent of intrinsic subtypes.
Methods
Patients
The present study was based upon a DBCG randomized,
phase III, multicenter trial previously described in detail[28]. The trial compared the efficacy of D to the combin-
ation of GD in 337 patients with histologically confirmed
locally advanced or metastatic breast cancer. Patients were
randomly assigned to D (100 mg/m2) day 1, every 21 days,
or G (1000 mg/m2) days 1 and 8 plus D (75 mg/m2) day 8,
every 21 days. Patients were either previously untreated,
had received prior (neo)adjuvant chemotherapy or a single
prior chemotherapy regimen, mostly anthracycline-based,
for metastatic breast cancer. The majority of patients had
HER2 normal (68.8%) and hormone receptor positive
disease (70.9%). More than half of the patients had visceral
disease (57.3%). The type and amount of post-study
chemotherapy were similar in the two arms. The study
was conducted in accordance with the Declaration of
Helsinki, and all patients gave their signed informed con-
sent prior to study entry. DBCG prepared the original
protocol as well as the biomarker supplement, and the
Danish National Committee on Biomedical Research Ethics
approved the original protocol and the supplement
(KF 02-045-01 and KF 12 315632/H-KF-02-045-01)
prior to activation.
TIMP-1 immunohistochemical staining
Expression of TIMP-1 protein was evaluated on formalin-
fixed, paraffin-embedded (FFPE) primary tumor tissue
whole sections (3 μm). The validated mouse monoclonal
antibody (clone VT7) raised against recombinant human
TIMP-1 [30,31] was applied for immunohistochemical
(IHC) staining as previously described [8]. In brief, sec-
tions were deparaffinized in xylene and rehydrated in
graded concentrations of ethanol. For antigen retrieval,
the sections were microwave treated in citrate buffer
pH = 6 and endogen peroidase activity was blocked by
hydrogen peroxide. Sections were incubated with VT7
(0.25 ug/ml) overnight at 4°C, and the antibody was de-
tected with mouse/rabbit Advanced HRP (Code No. 4068,
Dako A/S), and the reaction was visualized with DAB +
(Code No. K5007, Dako A/S). TIMP-1 was assessed semi
quantitatively using the positive (any cytoplasmatic staining
of tumor cells, > 0%) versus negative (no staining of tumor
cells) staining signal as a measure of the TIMP-1 immuno-
reactivity in the epithelial breast cancer cells [2,8,20]. The
whole-tissue sections were scanned and examined by light
microscopy and reviewed blinded, without knowledge of
patient characteristics and outcome, by three independent
investigators (pathologist EB and two trained observers,
technician AB and biologist CLTJ). The independent scores
from all three investigators were consolidated into a final
score. In case of discrepancies, agreement was reached by
the three investigators evaluating the slides together.
Statistics
Associations between TIMP-1 protein status and prog-
nostic and demographic variables of the main study [28]
FFPE primary tumor tissue 
available as whole tissue sections
n = 273 
Successful TIMP-1 IHC analysis
n = 264 
FFPE primary tumor 
tissue not 
available/unsuitable for 
TIMP-1 IHC
n = 64*
TIMP-1 IHC
unsuccessful/ 
withdrawn
n = 9**
TIMP-1 IHC positive: n = 210 
TIMP-1 IHC negative: n = 54 
DBCG clinical
trial population (ITT)
N = 337
(D: n=167; GD: n=170)
Figure 1 CONSORT diagram. *Tissue samples were unavailable/
unsuitable for one of the following reasons: archival tissue not
available (n = 39), no tumor cells in available samples (n = 13), only
needle biopsies available (n = 12). **Tissue samples were withdrawn for
one of the following reasons: IHC analysis done on metastasis only
(n = 3), patients with bilateral cancer (n = 4), IHC analysis unsuccessful
(n = 2). Abbreviations: D = docetaxel; DBCG = Danish Breast Cancer
Cooperative Group; FFPE = formalin-fixed, paraffin-embedded;
GD= gemcitabine plus docetaxel; IHC = immunohistochemical staining;
TIMP-1 = tissue inhibitor of metalloproteinases-1.
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tions between TIMP-1 and categorical variables (treatment
regimen, hormone receptor status, human epidermal
growth factor receptor 2 (HER2) status, type of metastatic
site, stage of disease, previous chemo-, hormonal-, and
radiation-therapy, and PAM50 intrinsic subtype) were
evaluated by Fisher’s exact test, while associations between
TIMP-1 and ordinal and interval variables (ECOG per-
formance status, age at randomization, number of meta-
static sites, and disease-free interval) were evaluated by the
Wilcoxon rank sum test.
Time to progression (TTP) was the primary endpoint
in the original trial [28] as well as in this biomarker sub-
study, and secondary endpoints were overall survival
(OS) and response rate (RR). TTP was measured from
date of randomization to date of documented progres-
sion with censoring at date of last visit or death. OS was
calculated from date of randomization to date of death
with censoring for surviving patients at last visit date.
Time-to-event endpoints (TTP and OS) were estimated
by the Kaplan-Meier method, and associations to TIMP-
1 status were evaluated by the log-rank test. Analyses of
TIMP-1 were done unadjusted as well as adjusted for
preselected covariates in multivariate Cox proportional
hazards models. The preselected covariates were those
found to be significant in the previous analysis of the
main study [28] and in a subsequent correlative sub-
study including PAM50 intrinsic subtype [29]: treatment
regimen, disease type (visceral vs. nonvisceral), stage of
disease, performance status, number of metastatic sites,
and PAM50 intrinsic subtype. The adjusted model was
further stratified for previous chemotherapy [28]. The
assumption of proportional hazards was assessed by
Schoenfeld residuals. Subgroup analyses were done to
assess whether treatment effects on TTP and OS dif-
fered according to TIMP-1 status or the levels of prese-
lected variables. In addition, explorative analysis of
treatment effect heterogeneity according to the com-
bined TIMP-1 and PAM50 intrinsic subtype status
(TIMP-1 positive and non-basal-like vs. TIMP-1 nega-
tive and/or basal-like) was evaluated. The multivariate
Cox proportional hazards model was extended by one
interaction term at a time. The interaction terms were
tested using the Wald test and results were given in a
Forest plot. RR was evaluated for patients with measur-
able disease. The overall RR was defined as a complete
or partial response according to RECIST criteria, version
1.0. RRs were compared by using Fisher’s exact test.
Statistical analyses were conducted using SAS version
9.2 software package (SAS Institute, Cary, NC, USA). All
statistical tests were two sided, and P < 0.05 considered
statistically significant. Reporting Recommendations for
Tumor Marker Prognostic Studies (REMARK) were ad-
hered to wherever applicable [32]. The design of the studywas prospective-retrospective as described by Simon et al.
[33].
Results
TIMP-1 IHC staining
Archival FFPE primary tumor tissue blocks from patients
enrolled in the trial were retrospectively collected between
January 2006 and December 2010 from study sites and
centrally stored. The original trial recruited 337 partici-
pants, and for the present study a total of 273 tumors were
available for TIMP-1 analysis (Figure 1). TIMP-1 IHC
staining was successful in 264 patients. The 264 TIMP-1
assessable patients differed significantly from the 73 non-
assessable patients (P < 0.05) with regard to stage of dis-
ease, (neo)adjuvant chemotherapy, adjuvant hormonal
therapy, and adjuvant radiation therapy (Table 1). Among
the assessable 264 patients, 210 (80%) had a TIMP-1-
positive tumor. TIMP-1 status was not correlated with
any of the baseline characteristics (Table 2).
Prognosis and response rates
In univariate analyses, TIMP-1 status was not associated
with TTP or OS, however, there was a non-significant
trend that TIMP-1 positive patients had increased OS
(P = 0.06) (Figure 2) (Table 3).
Table 1 Patient demographics, disease characteristics, and prior therapy
Included Excluded
Characteristics No. (%) No. (%) Pd
No. of patients 264 73
Regimen 0.36
Docetaxel and Gemcitabine 137 (51.9) 33 (45.2)
Docetaxel 127 (48.1) 40 (54.8)
Median age at randomization, years 59 57 0.57e
Range 30-75 36-73
ECOG performance status 0.84
0-1 223 (84.5) 65 (89.0)
2 32 (12.1) 8a (11.0)
Unknown 9 (3.4) 0 (0.0)
Stage of disease 0.049
Locally advanced 22 (8.3) 12 (16.4)
Metastatic 242 (91.7) 61 (83.6)
No. of metastatic sites 0.74
1 78 (29.5) 18 (24.7)
2 93 (35.2) 27 (37.0)
≥ 3 93 (35.2) 28 (38.4)
Type of metastatic site
Visceral 150 (56.8) 43 (58.9) 0.79
Lung 78 (29.5) 25 (34.2)
Liver 99 (37.5) 27 (37.0)
Non-visceral 114 (43.2) 30 (41.1)
Bone 175 (66.3) 41 (56.2)
Hormone receptor status 0.76
Positive 190 (72.0) 49 (67.1)
Negative 70 (26.5) 20 (27.4)
Unknown 4 (1.5) 4 (5.5)
HER2 statusb 0.77
Normal/deletion 212 (80.3) 20 (27.4)
Amplification 37 (14.0) 4 (5.5)
Unknown 15 (5.7) 49 (67.1)
PAM50 subtype 0.18
Luminal A 78 (29.5) 6 (8.2)
Luminal B 94 (35.6) 3 (4.1)
Basal-like 40 (15.2) 3 (4.1)
HER2-enriched 46 (17.4) 0 (0.0)
Unknown 6 (2.3) 61 (83.6)
Prior chemotherapy
Total 188 (71.2) 45 (61.6) 0.15
(Neo)adjuvant 127 (48.1) 17 (23.3) 0.0002
Anthracycline 71 (26.9) 11 (15.1)
Non-anthracycline 56 (21.2) 6 (8.2)
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Table 1 Patient demographics, disease characteristics, and prior therapy (Continued)
Locally advanced/metastatic 102 (38.6) 31 (42.5) 0.20
Anthracycline 86 (32.6) 30 (41.1)
Non-anthracycline 16 (6.1) 1 (1.4)
Hormonal therapy
Total 173 (65.5) 41 (56.2) 0.17
Adjuvant 119 (45.1) 19 (26.0) 0.006
Locally advanced/metastatic 120 (45.5) 37 (50.7) 0.43
Radiation therapy 157 (59.5) 22 (30.1) <0.0001
Disease-free interval, monthsc
Median 31 22 0.12e
Range 0-250 0-231
aIncluding one patient ECOG performance status 3.
bRetrospective analysis, primary tumor only.
cTime interval from diagnosis of primary cancer to recurrence.
dFisher's exact test, unknown values excluded from tests.
eWilcoxon test.
Abbreviations: ECOG Eastern Cooperative Oncology Group, HER2 Human epidermal growth factor receptor 2.
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to those found in the original study [28] (TTP: adjusted
HR = 0.60; 95% CI 0.42-0.84; P = 0.003; OS: adjusted HR =
0.88; 95% CI 0.67-1.15; P = 0.34) (Table 4).
In Cox multivariate analysis adjusted for regimen,
PAM50 subtype, presence of visceral disease, stage of
disease, number of metastatic sites, and ECOG perform-
ance status, TIMP-1 positivity was an independent prog-
nostic factor with regard to OS (adjusted HR = 0.71; 95%
CI 0.52-0.98; P = 0.03) but not for TTP (adjusted HR =
0.82; 95% CI 0.55-1.21; P = 0.31) (Table 4).
RR among the 164 patients with measurable disease did
not differ significantly according to TIMP-1 status (Table 5).
TIMP-1 subgroup analysis
In unadjusted analysis an estimated gain in median OS
of nine months was seen in the doublet arm compared
to the monotherapy arm for patients with a TIMP-1
negative tumor (GD, median OS: 19.9 months, 95% CI =
14.5-28.5; D, median OS: 10.6 months, 95% CI = 7.9-
16.5, log rank p = 0.053) (Figure 3A). No difference in
OS according to regimen was detected in patients with
TIMP-1 positive tumors (Figure 3B).
In multivariate Cox regression analyses adjusted for
the preselected covariates no interaction was demon-
strated between TIMP-1 status and treatment regimens
for TTP (Figure 4A). For OS a borderline significant
interaction was demonstrated such that GD improved
OS compared to D in patients with TIMP-1 negative tu-
mors (Figure 4B Pinteraction = 0.06).
Explorative analysis of gemcitabine responsive subgroup
In this trial we have previously demonstrated a substan-
tial reduction in mortality by GD compared to D inpatients with basal-like tumors [29]. In the current study
PAM50 intrinsic subtype remained an independent fac-
tor in the multivariate analysis with TIMP-1. To com-
pare TIMP-1 as a single marker against the combination
of TIMP-1 and PAM50 intrinsic subtype status further
explorative analyses were conducted. A total of 87 (33%)
patients were classified as G responsive (e.g. basal-like
subtype and/or lack of TIMP-1 immunoreactivity). In
Kaplan-Meier analysis patients classified as G responsive
had a significant improvement in both TTP (GD, median
TTP: 10.3 months, 95% CI = 7.7-12.6; D, median TTP:
6.2 months, 95% CI = 4.1-9.5) and OS (GD, median OS:
17.4 months, 95% CI = 14.4-20.7; D, median OS: 10.0
months, 95% CI = 7.9-15.5) if treated with GD compared
with D. Multivariate analysis adjusted for patient and
tumor characteristics confirmed these results for OS
(Pinteraction = 0.02, Figure 4B) but not for TTP (Pinteraction =
0.09, Figure 4A).
Discussion
In the present study, TIMP-1 cancer cell immunoreac-
tivity was associated with a reduction in mortality but
not with a reduction in TTP events (primary endpoint).
Furthermore, in patients without TIMP-1 cancer cell im-
munoreactivity, we identified a 46% relative reduction in
mortality from the addition of G to D compared to sin-
gle agent D, although this difference was not statistically
significant (Pinteraction = 0.06).
The majority of breast cancer studies on TIMP-1 and
association with prognosis and response to chemother-
apy have focused on patients receiving adjuvant chemo-
therapy [2,8,18,20,34], whereas only two studies have
included patients with advanced breast cancer [35,36].
These two studies both measured TIMP-1 levels in the
Table 2 Association between TIMP-1 status and patient demographics, disease characteristics, and prior therapy
TIMP-1 negative TIMP-1 positive
Characteristics No. (%) No. (%) Pc
No. of patients 54 210
Regimen 0.36
Docetaxel and Gemcitabine 25 (46.3) 112 (53.3)
Docetaxel 29 (53.7) 98 (46.7)
Median age at randomization, years 60 59 0.79e
Range 37-74 30-75
ECOG performance status 0.91
0-1 47 (87.0) 176 (83.8)
2 6 (11.1) 26 (12.4)
Unknown 1 (1.9) 8 (3.8)
Stage of disease 0.58
Locally advanced 3 (5.6) 19 (9.0)
Metastatic 51 (94.4) 191 (91.0)
No. of metastatic sites 0.40
1 12 (22.2) 66 (31.4)
2 22 (40.7) 71 (33.8)
≥ 3 20 (37.0) 73 (34.8)
Type of metastatic site
Visceral 31 (57.4) 119 (56.7) 1.00
Lung 17 (31.5) 61 (29.0) 0.87
Liver 18 (33.3) 81 (38.6) 0.44
Non-visceral 23 (42.6) 91 (43.3)
Bone 33 (61.1) 142 (67.6) 0.42
Hormone receptor status 0.30
Positive 42 (77.8) 148 (70.5)
Negative 11 (20.4) 59 (28.1)
Unknown 1 (1.9) 3 (1.4)
HER2 statusa 0.66
Normal/deletion 40 (74.1) 172 (81.9)
Amplification 8 (14.8) 29 (13.8)
Unknown 6 (11.1) 9 (4.3)
PAM50 subtype 0.89
Luminal A 15 (27.8) 63 (30.0)
Luminal B 20 (37.0) 74 (35.2)
Basal-like 7 (13.0) 33 (15.7)
HER2-enriched 11 (20.4) 35 (16.7)
Unknown 1 (1.9) 5 (2.4)
Prior chemotherapy
Total 37 (68.5) 151 (71.9) 0.62
(Neo)adjuvant 23 (42.6) 104 (49.5) 0.45
Anthracycline 14 (25.9) 57 (27.1)
Non-anthracycline 9 (16.7) 47 (22.4)
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Table 2 Association between TIMP-1 status and patient demographics, disease characteristics, and prior therapy
(Continued)
Locally advanced/metastatic 21 (38.9) 81 (38.6) 1.00
Anthracycline 15 (27.8) 71 (33.8)
Non-anthracycline 6 (11.1) 10 (4.8)
Hormonal therapy
Total 36 (66.7) 137 (65.2) 0.87
Adjuvant 24 (44.4) 95 (45.2) 1.00
Locally advanced/metastatic 27 (50.0) 93 (44.3) 0.54
Radiation therapy 33 (61.1) 124 (59.0) 0.88
Disease-free interval, monthsb
Median 36 31 0.41e
Range 0-224 0-250
aRetrospective analysis, primary tumor only.
bTime interval from diagnosis of primary cancer to recurrence.
cFisher's exact test, unknown values excluded from tests.
eWilcoxon test.
Abbreviations: ECOG Eastern Cooperative Oncology Group, HER2 Human epidermal growth factor receptor 2, TIMP-1 Tissue inhibitor of metalloproteinases-1.
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ent assay-based approach and included patients re-
ceiving cyclophosphamide/methotrexate/5-fluorouracil
or anthracycline-based chemotherapy. In the exploratory
study by Schrohl et al. [36] results suggested that patients
with high levels of TIMP-1 are less responsive to chemo-
therapy, but the study did not include an analysis of OS.
On the other hand, the second study by Klintman et al.
[35] which supports the association of TIMP-1 with ob-
jective response to chemotherapy, did not find TIMP-1 to
be associated with either progression free survival (PFS) or
OS. The results presented in this manuscript suggest that
TIMP-1 protein expression in cancer cells in the primary
tumor evaluated by IHC is associated with improved OS
for advanced breast cancer patients receiving D or GD.
The use of different methodologies and regimens does
compromise the comparability of studies, and thus, the
prognostic significance of TIMP-1 in advanced breast can-
cer remains unclear.
The predictive value of TIMP-1 in relation to chemo-
therapy has been evaluated in a few studies [2,8,20,21] but
to our knowledge the relationship between TIMP-1 and
the effect of G has not been addressed previously in a pre-
clinical or clinical setting. In the present study we found a
borderline statistically significant difference in OS favoring
GD over D alone for patients evaluated as TIMP-1 nega-
tive. TIMP-1 negative patients receiving GD increased
their survival by almost 50% to a median survival of
19.9 months compared to 10.6 months for patients receiv-
ing D only. Whether this survival benefit can be attributed
to the addition of G specifically or whether our findings
suggest a more general effect of chemotherapy doublets/D
containing doublets in advanced breast cancer remains
speculative and hypothesis generating. We were, however,able to identify a subgroup of patients that derived clinic-
ally meaningful benefit from combination chemotherapy
as compared to single agent chemotherapy using TIMP-1
immunoreactivity although the results did not reach stat-
istical significance (P = 0.06).
Preclinical data suggest that the anti-apoptotic functions
of TIMP-1 are mediated through the phosphatidylinositol
3-kinase (PI3K)/Akt survival pathway [15,37] and TIMP-1
in this manner protects cancer cells from the effects of
chemotherapy and hence cancer cells lacking TIMP-1
would remain sensitive to chemotherapy. Interestingly,
the PI3K/Akt pathway has previously been suggested to
be implicated in gemcitabine resistance [38]. Other pre-
clinical findings suggest that TIMP-1 modifies prolifera-
tion by direct regulation of the cell cycle by arresting cells
in G1 phase [39]. This could possibly alter the response to
cell cycle specific drugs such as G, as the cytotoxic effect
of G is associated primarily with specific inhibition of cells
in the S phase [25,40]. Furthermore, low levels of TIMP-1
have been associated with sensitivity to anthracycline-
[2,8,20,21] and irinotecan-containing therapy [41]. Since
anthracyclines are topoisomerase-2 inhibitors and irinote-
can is a topoisomerase-1 inhibitor, TIMP-1 may particu-
larly interact with topoisomerase inhibitors. G has been
shown to poison topoisomerase I [42,43], suggesting that
TIMP-1 can influence the effect of G through this en-
zyme. Taken together, these findings, along with the re-
sults obtained in the present study, make a ‘broader’
predictive role of TIMP-1 in the treatment of breast can-
cer likely.
Clinical trials in advanced breast cancer and other
solid tumors often use TTP and PFS as primary end-
points and surrogate markers for OS [44,45]. However,
an increase in TTP or PFS does not always translate into
Figure 2 Time to progression and overall survival according to TIMP-1 status. Kaplan-Meier curve for (A) time to progression (165 events)
and (B) overall survival (240 events) for all 264 advanced breast cancer patients treated with gemcitabine plus docetaxel or docetaxel alone (study
arms combined) according to TIMP-1 immunohistochemical staining status. Abbreviations: CI = confidence interval; TIMP-1 = tissue inhibitor
of metalloproteinases-1.
Table 3 Cox univariate models for time to progression and overall survivala
Time to progression Overall survival
Risk factor n HR 95% CI P HR 95% CI P
TIMP-1 (positive vs. negative) 264 0.90 (0.61- 1.31) 0.57 0.742 (0.55- 1.01) 0.06
aModels not stratified.
Abbreviations: CI Confidence interval, HR Hazard ratio, TIMP-1 Tissue inhibitor of metalloproteinases-1.
Jørgensen et al. BMC Cancer 2014, 14:360 Page 8 of 14
http://www.biomedcentral.com/1471-2407/14/360
Table 4 Cox multivariable models for time to progression and overall survivala
Time to progression Overall survival
Risk factor n HR 95% CI P HR 95% CI P
Regimen (GD vs. D) 0.60 (0.42- 0.84) 0.003 0.88 (0.67- 1.15) 0.34
TIMP-1 (positive vs. negative) 0.82 (0.55- 1.21) 0.31 0.71 (0.52- 0.98) 0.03
PAM50 0.007 0.0001
Luminal A 78 0.68 (0.45- 1.04) 0.08 0.78 0.56 1.08 0.14
Luminal B 100b 1.00 referent 1.00 referent
Basal-like 40 1.75 (1.05- 2.92) 0.03 2.39 (1.56- 3.64) <0.0001
HER2-enriched 46 1.30 (0.82- 2.07) 0.27 1.25 (0.85- 1.84) 0.25
Visceral disease (yes vs. no) 1.60 (1.07- 2.39) 0.02 1.13 (0.84- 1.53) 0.42
Stage of disease (locally advanced vs. metastatic) 1.96 (1.02- 3.76) 0.04 0.72 (0.42- 1.24) 0.23
Metastatic sites (3+ vs. 1-2) 1.24 (0.86- 1.77) 0.25 1.52 (1.13- 2.04) 0.01
ECOG performance status (2 vs. 0-1) 1.19 (0.85- 1.67) 0.31 1.47 (1.12- 1.93) 0.006
aModels stratified for previous chemotherapy (none, n = 76; adjuvant, n = 86; locally advanced or metastatic, n = 102).
bIncluding 6 records with missing value of PAM50 molecular subtype.
Abbreviations: CI Confidence interval, D Docetaxel, ECOG Eastern Cooperative Oncology Group, G Gemcitabine, HER2 Human epidermal growth factor receptor 2,
HR Hazard ratio, TIMP-1 Tissue inhibitor of metalloproteinases-1.
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http://www.biomedcentral.com/1471-2407/14/360a survival benefit. On the other hand, the results pre-
sented here demonstrate that neither the prognostic im-
pact of TIMP-1 nor the trend of interaction between
TIMP-1 status and treatment regarding OS were
reflected in the analysis of the primary endpoint TTP. A
reason for this discrepancy could be related to the nine-
weekly disease-evaluations used in the current trial,
which may have generated a systematic bias and less
precise evaluation of TTP as compared to the OS end-
point where the date of death is exact [44]. Given that
both tumor promoting and inhibitory effects have been
described for TIMP-1 [12-16], and that cellular TIMP-1
function depends on the surrounding microenvironment
[46,47] the discrepancy between endpoints could also be
related to a biological role of TIMP-1 such that the role
of TIMP-1 is different in the case of localized cancerTable 5 Best overall responsea by TIMP-1 protein statusb
TIMP-1 Positive TIMP-1 Negative
Response No. (%) No. (%)
CR 4 (3.0) 2 (6.3)
PR 46 (34.8) 9 (28.1)
Total responses 50 (37.9) 11 (34.4)
(95% CI) (24.2 to 40.8) (30.7 to 69.4)
SD 56 (42.4) 15 (46.9)
PD 15 (11.4) 5 (15.6)
Unknown 11 (8.3) 1 (3.1)
Total 132 32
aMeasurable disease (n = 164).
bTotal responses, Fisher's exact test P =0.84.
Abbreviations: CI Confidence interval, CR Complete response, PD Progressive
disease, PR Partial response, SD Stable disease, TIMP-1 Tissue inhibitor
of metalloproteinases-1.compared to the advanced disease setting, perhaps by
preventing further spread of metastasis at this stage.
We have previously shown in this trial a differential
benefit from the addition of G to D in patients with a
basal-like intrinsic subtype classified by the PAM50
assay [29]. The fact that TIMP-1 status was not associ-
ated with PAM50 intrinsic subtype, suggests that TIMP-
1 negative status and the basal-like subtype characterize
two biologically distinct mechanisms of a possible G re-
sponsiveness. For comparison, in an exploratory analysis,
we combined TIMP-1 and PAM50 subtype into a panel
and classified patients as G responsive if tumors lacked
TIMP-1 immunoreactivity and/or were characterized as
basal-like, or otherwise as G nonresponsive. Using this
panel 33% of the patients could be classified as G re-
sponsive compared with 20% and 15% using TIMP-1
status or PAM50 intrinsic subtype classification, respect-
ively. The benefit from GD compared to D was consider-
ably larger in patients with a G responsive profile, and
this heterogeneity was confirmed by a statistically signifi-
cant test of interaction between this panel and treatment
for OS. Thus, the PAM50 intrinsic subtype/TIMP-1 pro-
tein status panel identifies the patients most likely to
benefit from GD compared to D in terms of OS, and
additionally, this panel appears to identify and separate
two-thirds of the patients unlikely to derive any benefit
from this combination therapy.
A strength of this study is that data from 78% of the
patients enrolled in a randomized phase III clinical trial
with long-term follow-up were available for analysis. In
addition, we applied a previously validated assay for
TIMP-1 immunoreactivity. On the other hand this study
also has some potential limitations. The statistical power
was limited due to the small population size, especially
Figure 3 Overall survival according to TIMP-1 status and treatment. Kaplan-Meier curve for overall survival for (A) TIMP-1 negative patients
and (B) TIMP-1 positive patients according to treatment allocation. Abbreviations: CI = confidence interval; D = docetaxel; DG = docetaxel plus
gemcitabine; TIMP-1 = tissue inhibitor of metalloproteinases-1; trt = treatment.
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http://www.biomedcentral.com/1471-2407/14/360under-powering the results of the subgroup analysis. An-
other limitation is the fact that we did not include
TIMP-1 staining of stromal cells in the analyses. It has
been suggested that TIMP-1 may be produced by stro-
mal cells and eventually become absorbed by breast can-
cer cells [48], and an association between stromal
TIMP-1 expression status and progression of cancer has
been reported [49,50], although not consistently [51,52].In the current study TIMP-1 expression was exclusively
evaluated in breast cancer cells, and the outcome might
have been different if TIMP-1 had been evaluated in
stromal cells or in stromal as well as cancer cells. Fur-
thermore, TIMP-1 analysis was performed on primary
tumor tissue and not on corresponding metastases. We
cannot be sure that the status of TIMP-1 will be the
same in the metastases as in the primary tumor since
All patients
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Figure 4 (See legend on next page.)
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Figure 4 Subgroup analyses. Forest plots illustrating hazard ratio (HR) estimates of treatment effect with 95% confidence intervals (CI) for
(A) time to progression and (B) overall survival comparison between patients with TIMP-1 negative and TIMP-1 positive tumors, basal-like and
non-basal-like tumors, TIMP-1 negative and/or basal-like (G responsive) and TIMP-1 positive and non-basal-like tumors (G nonresponsive).
Abbreviations: D = docetaxel; G = gemcitabine; TIMP-1 = tissue inhibitor of metalloproteinases-1.
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pronouncedly in the period in between primary diagnosis
and recurrence, especially as a majority of the patients re-
ceived prior treatment. A substantial discordance in ER
and HER2 status between primary and metastatic tumor
tissue has been reported [53-55], and a study has demon-
strated differences in the immunoreactivity of TIMP-1 in
primary breast tumor tissue and the corresponding axil-
lary lymph node metastasis [56]. TIMP-1 expression in
primary and metastatic tumor tissue have not been com-
pared, but usage of metastatic tumor tissue could poten-
tially have had an impact on the results.
Conclusions
In summary, this retrospective analysis applied to a pro-
spective clinical trial demonstrated that TIMP-1 status ap-
pears to contain an independent prognostic value regarding
overall survival in patients with advanced breast cancer re-
ceiving chemotherapy. We demonstrated that OS was al-
most doubled for patients with a TIMP-1 negative status
receiving the combination regimen as compared to single
agent chemotherapy. However, the test for interaction be-
tween TIMP-1 status and treatment did only reach border-
line significance. Furthermore, we could not show a similar
reduction in TTP events, the pre-specified primary end-
point of this study. The results presented here need further
validation in order to obtain convincing evidence that
TIMP-1 may be used as a predictive marker to direct the
use of G in combination with D for patients with advanced
breast cancer.
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